S. R. D'sa et al., 2014-08-12: Observational case series of five patients with severe toxin-induced methemoglobinemia (nitrobenzene, benzoylphenylurea, flubendamide and an unnamed compound) treated with repeated methylene blue doses, with haemolysis in all and survival in all.
All patients were treated with methylene blue; 4 received more than one dose.
Abstract
S. R. D'sa et al., 2014-08-12: Observational case series of five patients with severe toxin-induced methemoglobinemia (nitrobenzene, benzoylphenylurea, flubendamide and an unnamed compound) treated with repeated methylene blue doses, with haemolysis in all and survival in all. Observational case series; 5 patients out of 824 poisoning admissions with methemoglobin 49% or more (median 64.7%, range 49.8-91.6%). Country: India (Christian Medical College, Vellore). Dose: methylene blue, repeat doses in 4 of 5 (mg/kg per the treating protocol, not stated in the abstract); intravenous. Funder/conflicts: not stated in the record. Comparator: none (case series). This is the documented role the record should carry for C10: methylene blue is an antidote for toxin-induced methemoglobinemia, not a chelator. Note also that haemolysis occurred in all five – itself a known methylene blue adverse effect. Study type: uncontrolled series.
